Département d'Anesthésie et de Réanimation, Hôpitaux Universitaires Paris-Sud, Université Paris-Sud, Hôpital de Bicêtre, Assistance Publique, Hôpitaux de Paris, Le Kremlin-Bicêtre, France -
Minerva Anestesiol. 2016 Nov;82(11):1214-1229. Epub 2016 Sep 8.
Viscoelastic hemostatic assays (VHAs), mainly thromboelastography (TEG) and the rotational thromboelastometry (ROTEM), provide global information on clot formation and dissolution at patient bedside, allowing fast identification of coagulation disorders. In trauma patients, VHAs are able to predict massive transfusion and mortality. These devices might also be used for applying targeted administration of procoagulant factors (e.g. fibrinogen concentrate) as an alternative to or in addition to using predefined fixed ratios of red blood cells: platelets: fresh frozen plasma/cryoprecipitate. These goal-directed, individualized treatment algorithms seem to reduce blood product transfusion without deleterious effects on patient outcome. Nevertheless, a clear outcome benefit of using VHAs remains to be demonstrated in trauma patients.
黏弹性止血检测(VHA),主要包括血栓弹力描记法(TEG)和旋转血栓弹性测定法(ROTEM),可在患者床边提供关于血凝块形成和溶解的整体信息,有助于快速识别凝血障碍。在创伤患者中,VHA 能够预测大出血和死亡。这些设备还可用于靶向给予促凝因子(例如纤维蛋白原浓缩物),以替代或补充使用预先设定的红细胞:血小板:新鲜冷冻血浆/冷沉淀的固定比例。这些基于目标的个体化治疗算法似乎可以减少血液制品的输注,而不会对患者的预后产生不良影响。然而,在创伤患者中,使用 VHA 是否有明确的临床获益仍有待证明。